Literature DB >> 18024095

Kaplan-Meier analysis on seizure outcome after epilepsy surgery: do gender and race influence it?

Jorge G Burneo1, Vicente Villanueva, Robert C Knowlton, R Edward Faught, Ruben I Kuzniecky.   

Abstract

OBJECTIVE: To evaluate seizure outcome following epilepsy surgery for patients with temporal lobe epilepsy and evaluate is gender and race/ethnicity influence it.
METHODS: Data were obtained from the discharge database of the University of Alabama at Birmingham, Epilepsy Center, between 1985 and 2001. The sample consisted of all patients with a primary diagnosis of medically intractable temporal lobe epilepsy (TLE) who underwent anterior temporal lobectomy. Seizure recurrence was tabulated at 7 days, 2 months, 6 months, 1, 2, 3, 4, 5, and 6 years following surgery. Logistic regression analysis was used to model the presence of seizure recurrence after anterior temporal lobectomy for all patients. Kaplan-Meier analysis was done to obtain estimates and 95% CIs of seizure freedom from baseline. Baseline variables--age at surgery, age at seizure onset, sex, side of resection, immediate postoperative seizures, and pathology results--were assessed as potential predictors of each outcome by comparing the survival curves within each variable with a log rank test.
RESULTS: Three hundred sixty-eight patients underwent surgical treatment for TLE, mean age of 30.2 years. Thirty-five patients were African American, 43% were men. Immediate postoperative seizures were seen in 23 patients, while seizure recurrence occurred in 27.3% patients within a year after surgery, and in 33.6% within 6 years. Logistic regression results showed no differences between African Americans and whites, between males and females. The occurrence of immediate postoperative seizures was a strong predictor of late seizure recurrence only at 1 year after surgery.
CONCLUSIONS: The occurrence of seizures in the immediate postoperative period is a strong predictor of later seizure recurrence. Sex and race/ethnicity do not appear to be predictors of long-term outcome following surgery for temporal lobe epilepsy.

Entities:  

Mesh:

Year:  2007        PMID: 18024095     DOI: 10.1016/j.seizure.2007.10.002

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  5 in total

1.  High Risk of Seizures and Epilepsy after Decompressive Hemicraniectomy for Malignant Middle Cerebral Artery Stroke
.

Authors:  Rosane Brondani; Andrea Garcia de Almeida; Pedro Abrahim Cherubini; Suelen Mandelli Mota; Luiz Carlos de Alencastro; Apio Cláudio Martins Antunes; Marino Bianchin Muxfeldt
Journal:  Cerebrovasc Dis Extra       Date:  2017-03-30

2.  Initiating an epilepsy surgery program with limited resources in Indonesia.

Authors:  Muhamad Thohar Arifin; Ryosuke Hanaya; Yuriz Bakhtiar; Aris Catur Bintoro; Koji Iida; Kaoru Kurisu; Kazunori Arita; Jacob Bunyamin; Rofat Askoro; Surya Pratama Brilliantika; Novita Ikbar Khairunnisa; Zainal Muttaqin
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

3.  Cost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the US.

Authors:  Shehryar R Sheikh; Michael W Kattan; Michael Steinmetz; Mendel E Singer; Belinda L Udeh; Lara Jehi
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

4.  Long-term seizure outcome following resective surgery for epilepsy: to be or not to be completely cured?

Authors:  Takeharu Kunieda; Nobuhiro Mikuni; Sumiya Shibata; Rika Inano; Yukihiro Yamao; Takayuki Kikuchi; Riki Matsumoto; Jun Takahashi; Akio Ikeda; Hidenao Fukuyama; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-10-21       Impact factor: 1.742

5.  Periventricular [(11)C]flumazenil binding for predicting postoperative outcome in individual patients with temporal lobe epilepsy and hippocampal sclerosis.

Authors:  Josiane Yankam Njiwa; Sandrine Bouvard; Hélène Catenoix; François Mauguiere; Philippe Ryvlin; Alexander Hammers
Journal:  Neuroimage Clin       Date:  2013-09-03       Impact factor: 4.881

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.